AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25366641 — intervention group
Group type: COMPARATOR
Intervention: No delayed cerebral infarction (Control)
Number of subjects: 120
Study 25366688 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m², once every 3 weeks)
Number of subjects: 1066
Study 25366688 — intervention group
Group type: EXPERIMENTAL
Intervention: No DTCs after treatment with docetaxel
Number of subjects: 1066
Study 25366688 — intervention group
Group type: COMPARATOR
Intervention: No DTCs at BM1 and BM2
Number of subjects: 1066
Study 25367064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough during therapeutic thoracentesis
Number of subjects: 0
Study 25367412 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 785
Study 25367412 — intervention group
Group type: COMPARATOR
Intervention: Methoxy polyethylene glycol-epoetin beta (PEG-Epo)
Number of subjects: 785
Study 25368957 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a for 48 weeks
Number of subjects: 95
Study 25368957 — intervention group
Group type: EXPERIMENTAL
Intervention: PARC rule evaluated in a subset of 47 patients
Number of subjects: 95
Study 25369108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg, subcutaneously every 4 weeks for 6 months
Number of subjects: 43
Study 25369558 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired daily spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs) in collaborative units.
Number of subjects: 5164
Study 25369558 — intervention group
Group type: COMPARATOR
Intervention: Surveillance-only units (control group).
Number of subjects: 5164
Study 25369725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapies tailored to caregiver thinking patterns
Number of subjects: 90
Study 25369725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapies
Number of subjects: 90
Study 25370510 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral-domain OCT (SD-OCT)
Number of subjects: 126
Study 25370510 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary algorithm-derived measurements
Number of subjects: 126
Study 25370510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 126
Study 25370513 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT) with 3-D segmentation algorithm
Number of subjects: 126
Study 25370536 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive in-hospital assessment including clinical characteristics, geriatric impairments, and health status measures.
Number of subjects: 3000
Study 25370536 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for six months post-hospitalization.
Number of subjects: 3000
Study 25370584 — intervention group
Group type: EXPERIMENTAL
Intervention: Actical accelerometers attached to both wrists, ankles, and hip for ≤7 days
Number of subjects: 100
Study 25370626 — intervention group
Group type: EXPERIMENTAL
Intervention: Kilovoltage intrafraction monitoring (KIM)
Number of subjects: 0
Study 25370961 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC treatment
Number of subjects: 20
Study 25371383 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS over the left motor cortex and contralateral supraorbital cortex for 5 days
Number of subjects: 12
Study 25371383 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over the left motor cortex for 5 days after sham tDCS
Number of subjects: 12
Study 25371383 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 12
Study 25371383 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study 25371383 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anterior cingulate Glx levels
Number of subjects: 12
Study 25371447 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 180
Study 25371447 — intervention group
Group type: COMPARATOR
Intervention: Estrogens, progesterone, non-SHBG-bound testosterone, SHBG
Number of subjects: 180
Study 25371447 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 180
Study 25371817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 70
Study 25371966 — intervention group
Group type: EXPERIMENTAL
Intervention: PER977
Number of subjects: 0
Study 25371966 — intervention group
Group type: COMPARATOR
Intervention: edoxaban
Number of subjects: 0
Study 25372029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with SP and SP-PQ
Number of subjects: 616
Study 25372029 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infection
Number of subjects: 616
Study 25372029 — intervention group
Group type: EXPERIMENTAL
Intervention: S. mansoni infection
Number of subjects: 616
Study 25372980 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-contrast MR imaging-derived duration of vortical blood flow (tvortex)
Number of subjects: 145
Study 25372980 — intervention group
Group type: EXPERIMENTAL
Intervention: tvortex-based diagnosis of PH
Number of subjects: 145
Study 25372980 — intervention group
Group type: EXPERIMENTAL
Intervention: tvortex < 14.3%
Number of subjects: 145
Study 25373117 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD/SRI exposure
Number of subjects: 166
Study 25373117 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD/no SRI exposure
Number of subjects: 166
Study 25373117 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed infants
Number of subjects: 166
Study 25373390 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages sent as an adjunct to group Cognitive Behavioral Therapy (CBT) for depression.
Number of subjects: 39
Study 25374341 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg orally twice daily until disease progression or drug intolerance
Number of subjects: 12
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic agents initiated in the prehospital phase
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylic salicylic acid (ASA)
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Any GP IIb/IIIa inhibitor
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual combination of ASA+(clopidogrel/prasugrel)
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I/ARB
Number of subjects: 629
Study 25374386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of five drug classes (ASA, P2Y12 antagonists, statin, beta blocker, ACE-I/ARB)
Number of subjects: 629
Study 25374386 — intervention group
Group type: COMPARATOR
Intervention: Bleeding complications
Number of subjects: 629
Study 25374771 — intervention group
Group type: EXPERIMENTAL
Intervention: Homonymous visual field defects (HVFDs) patients
Number of subjects: 20
Study 25374771 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided HVFD patients who passed the test
Number of subjects: 20
Study 25374771 — intervention group
Group type: COMPARATOR
Intervention: Healthy-sighted control subjects
Number of subjects: 20
Study 25375257 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip system
Number of subjects: 58
Study 25375865 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen endotracheal tube (DLET)
Number of subjects: 20
Study 25375865 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal tube (ETT)
Number of subjects: 20
Study 25375983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals of 511, 743, and 1034 kcal
Number of subjects: 24
Study 25376399 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss surgery
Number of subjects: 242
Study 25376618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR (60 mg every 4 weeks)
Number of subjects: 29
Study 25377157 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral panobinostat (single dose)
Number of subjects: 37
Study 25377157 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral panobinostat (thrice weekly)
Number of subjects: 37
Study 25377157 — intervention group
Group type: EXPERIMENTAL
Intervention: BJB432 (metabolite of panobinostat)
Number of subjects: 37
Study 25377177 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests for DR-TB
Number of subjects: 0
Study 25377177 — intervention group
Group type: COMPARATOR
Intervention: Current standard mycobacterial growth indicator tube (MGIT) drug susceptibility tests
Number of subjects: 0
Study 25377187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic infusions of FXIII concentrate (human) 40 IU kg(-1) every 4 weeks for 12 months
Number of subjects: 41
Study 25377187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic infusions of FXIII concentrate (human)
Number of subjects: 41
Study 25377767 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical training program
Number of subjects: 25
Study 25378645 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3 (replicative defective simian adenoviral vector) followed by MVA (modified vaccinia Ankara) vector
Number of subjects: 0
Study 25378645 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3 followed by MVA
Number of subjects: 0
Study 25378660 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 837
Study 25378660 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2-positive participants
Number of subjects: 837
Study 25378660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-married adolescents
Number of subjects: 837
Study 25378660 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study participants
Number of subjects: 837
Study 25378660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational level and exam scores
Number of subjects: 837
Study 25379192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower 25(OH)D levels
Number of subjects: 170
Study 25379192 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D status
Number of subjects: 170
Study 25379854 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS (Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy)
Number of subjects: 202
Study 25379854 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS (in patients younger than 60 years with CRLM)
Number of subjects: 202
Study 25379854 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 202
Study 25379861 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 71
Study 25380183 — intervention group
Group type: EXPERIMENTAL
Intervention: LGX818 (300 mg daily)
Number of subjects: 1
Study 25380224 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversal abdominal (TrA) muscle activation in LBP patients
Number of subjects: 73
Study 25380224 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversal abdominal (TrA) muscle activation in pain-free participants
Number of subjects: 73
Study 25380224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar multifidus (LM) muscle activation in LBP patients
Number of subjects: 73
Study 25380224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar multifidus (LM) muscle activation in pain-free participants
Number of subjects: 73
Study 25380582 — intervention group
Group type: COMPARATOR
Intervention: CAG repeat length 27-35
Number of subjects: 2167
Study 25380582 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat length 36-39
Number of subjects: 2167
Study 25380582 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 65 years or more
Number of subjects: 2167
Study 25380582 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2167
Study 25380582 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education (university degree or higher)
Number of subjects: 2167
Study 25380636 — intervention group
Group type: EXPERIMENTAL
Intervention: Farletuzumab (administered by intravenous injection, dose escalation planned in 4 cohorts: 50, 100, 200, and 400 mg/m(2))
Number of subjects: 16
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 negative and intestinal type (Group A)
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive and intestinal type (Group B)
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 negative and diffuse type (Group C)
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive and diffuse type (Group D)
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 negative and mixed type (Group E)
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive and mixed type (Group F)
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: L-H status (combined Lauren classification and HER2 status)
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 status in intestinal type patients
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 status in diffuse type patients
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: L-H status vs Lauren classification
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 negative and intestinal type
Number of subjects: 838
Study 25380654 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive and diffuse type
Number of subjects: 838
Study 25380704 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal paced QRS axis
Number of subjects: 187
Study 25380704 — intervention group
Group type: COMPARATOR
Intervention: Abnormal paced QRS axis
Number of subjects: 187
Study 25380704 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal paced QRS axis among non-apical pacing
Number of subjects: 187
Study 25380748 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal vaporizers (PVs)
Number of subjects: 50
Study 25380809 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST symptoms
Number of subjects: 5023
Study 25381092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-isotope high-speed myocardial perfusion imaging (MPI)
Number of subjects: 214
Study 25381092 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 214
Study 25381131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosaroxin (80-90 mg/m²) plus cytarabine (schedule A: 400 mg/m²/day, days 1-5; schedule B: 1 g/m²/day, days 1-5)
Number of subjects: 110
Study 25382351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial therapy (IT)
Number of subjects: 937
Study 25382351 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 937
Study 25382415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother Program (MP)
Number of subjects: 202
Study 25382415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Plus-Child Program (MPCP)
Number of subjects: 202
Study 25382415 — intervention group
Group type: COMPARATOR
Intervention: Literature Control (LC)
Number of subjects: 202
Study 25383091 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (H)
Number of subjects: 42
Study 25383091 — intervention group
Group type: COMPARATOR
Intervention: Monopolar Diathermy (MD)
Number of subjects: 42
Study 25383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction program (diet control and exercise)
Number of subjects: 32
Study 25384705 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion irradiation, median dose 36 Gy (RBE), range 36-51 Gy (RBE)
Number of subjects: 19
Study 25384705 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion irradiation
Number of subjects: 19
Study 25384812 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk assessment
Number of subjects: 1707
Study 25385094 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir (240 mg QD for 8 days following a 480-mg loading dose) with methadone
Number of subjects: 34
Study 25385094 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir (240 mg QD for 8 days following a 480-mg loading dose) with buprenorphine-naloxone
Number of subjects: 34
Study 25385094 — intervention group
Group type: COMPARATOR
Intervention: Faldaprevir coadministration
Number of subjects: 34
Study 25385099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE) and Levonorgestrel (LNG) coadministered with 240 mg faldaprevir QD
Number of subjects: 16
Study 25385099 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol (EE) and Levonorgestrel (LNG) alone
Number of subjects: 16
Study 25385103 — intervention group
Group type: EXPERIMENTAL
Intervention: Miravirsen
Number of subjects: 0
Study 25385345 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP2B1 rs12817819 A allele
Number of subjects: 1741
Study 25385345 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of INVEST and WISE
Number of subjects: 1741
Study 25385345 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression analysis
Number of subjects: 1741
Study 25385409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (plasma glucose 16 mmol/l)
Number of subjects: 8
Study 25385439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 13
Study 25385439 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 13
Study 25385737 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 36
Study 25386767 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir-ABT-450/r and dasabuvir with ribavirin for 24 weeks
Number of subjects: 34
Study 25386767 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir-ABT-450/r and dasabuvir with ribavirin
Number of subjects: 34
Study 25386899 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Intervention Group (MIG) - goal to increase child's activity to 6000 pedometer steps/day above baseline, daily monitoring by parents
Number of subjects: 27
Study 25386899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Intervention Group (IIG) - same steps/day and monitoring goals as MIG, plus text messages and articles with behavioral strategies
Number of subjects: 27
Study 25386899 — intervention group
Group type: COMPARATOR
Intervention: Comparison between MIG and IIG
Number of subjects: 27
Study 25387065 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-GST
Number of subjects: 405
Study 25387065 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-SCT
Number of subjects: 405
Study 25387065 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 405
Study 25387217 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (subcutaneous administration, once-weekly)
Number of subjects: 0
Study 25387217 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 0
Study 25387261 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP in children with achondroplasia
Number of subjects: 96
Study 25387261 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP in adults with achondroplasia
Number of subjects: 96
Study 25387261 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP in children with hypochondroplasia
Number of subjects: 96
Study 25387261 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP in children with AMDM
Number of subjects: 96
Study 25387866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib prophylaxis after allogeneic stem cell transplantation (SCT)
Number of subjects: 22
Study 25387866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib prophylaxis after SCT
Number of subjects: 22
Study 25387901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation
Number of subjects: 143
Study 25387993 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal reduction therapy (septal myectomy or alcohol septal ablation)
Number of subjects: 77
Study 25387993 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic intervention and medical therapy for hypertrophic cardiomyopathy
Number of subjects: 77
Study 25388099 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH) 0.58 mg, intralesional injections, administered in cycles of two injections 24-72 hours apart, repeated after 6 weeks for ≤4 cycles.
Number of subjects: 238
Study 25388099 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH) 0.58 mg, intralesional injections.
Number of subjects: 238
Study 25388167 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04449913 640 mg once daily
Number of subjects: 23
Study 25388167 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04449913 320 mg once daily
Number of subjects: 23
Study 25388167 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04449913 80 to 320 mg once daily
Number of subjects: 23
Study 25388167 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04449913
Number of subjects: 23
Study 25389254 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination for HCWs with anti-HBs <12 mIU/mL
Number of subjects: 59
Study 25389254 — intervention group
Group type: COMPARATOR
Intervention: Initial vaccination
Number of subjects: 59
Study 25389443 — intervention group
Group type: EXPERIMENTAL
Intervention: Zembrin 25 mg daily for 3 weeks
Number of subjects: 21
Study 25389443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21